Sign up to access all valuation multiples
Susmed Inc is engaged in the development of therapeutic smartphone apps and digital solutions to streamline clinical trials. It is currently developing therapeutic apps for patients with insomnia, breast cancer, kidney disease, and other conditions. In addition, it has developed Susumed System, which uses a proprietary blockchain technology to ensure the reliability of clinical trial data, and can reduce the manpower and costs allocated to clinical trials. The company's reportable segments are: the DTx Product Business, which derives maximum revenue, and consists of the development of therapeutic apps; and the DTx Platform Business, which provides general-purpose clinical trial systems and machine learning automated analysis systems.
2015
39
LTM Revenue $3.7M
Last FY EBITDA -$2.4M
$64.1M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Susmed has a last 12-month revenue (LTM) of $3.7M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Susmed achieved revenue of $2.3M and an EBITDA of -$2.4M.
Susmed expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Susmed valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $3.7M | XXX | $2.3M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $2.2M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 97% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | -$2.4M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -105% | XXX | XXX | XXX |
| EBIT | -$1.7M | XXX | -$2.5M | XXX | XXX | XXX |
| EBIT Margin | -46% | XXX | -107% | XXX | XXX | XXX |
| Net Profit | -$1.7M | XXX | -$2.4M | XXX | XXX | XXX |
| Net Margin | -45% | XXX | -104% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of August 29, 2025, Susmed's stock price is JPY 837 (or $6).
Susmed has current market cap of JPY 14.1B (or $94.8M), and EV of JPY 9.5B (or $64.1M).
See Susmed trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $64.1M | $94.8M | XXX | XXX | XXX | XXX | $-0.10 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of August 29, 2025, Susmed has market cap of $94.8M and EV of $64.1M.
Susmed's trades at 21.8x EV/Revenue multiple, and -47.3x EV/EBITDA.
Equity research analysts estimate Susmed's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Susmed has a P/E ratio of -56.4x.
See valuation multiples for Susmed and 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $94.8M | XXX | $94.8M | XXX | XXX | XXX |
| EV (current) | $64.1M | XXX | $64.1M | XXX | XXX | XXX |
| EV/Revenue | 17.3x | XXX | 21.8x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | -47.3x | XXX | XXX | XXX |
| EV/EBIT | -38.0x | XXX | -46.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | -56.4x | XXX | -68.9x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -120.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialSusmed's last 12 month revenue growth is 112%
Susmed's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.
Susmed's rule of 40 is 66% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Susmed's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Susmed and other 15K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 112% | XXX | 87% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | -46% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 66% | XXX | 66% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 71% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 203% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Alcidion Group | XXX | XXX | XXX | XXX | XXX | XXX |
| CurveBeam AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Doctor Care Anywhere | XXX | XXX | XXX | XXX | XXX | XXX |
| Echo IQ | XXX | XXX | XXX | XXX | XXX | XXX |
| Mach7 Technologies | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Susmed acquired XXX companies to date.
Last acquisition by Susmed was XXXXXXXX, XXXXX XXXXX XXXXXX . Susmed acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 65K+ M&A deals.
Start Free Trial| When was Susmed founded? | Susmed was founded in 2015. |
| Where is Susmed headquartered? | Susmed is headquartered in Japan. |
| How many employees does Susmed have? | As of today, Susmed has 39 employees. |
| Is Susmed publicy listed? | Yes, Susmed is a public company listed on TKS. |
| What is the stock symbol of Susmed? | Susmed trades under 4263 ticker. |
| When did Susmed go public? | Susmed went public in 2021. |
| Who are competitors of Susmed? | Similar companies to Susmed include e.g. Alcidion Group, CurveBeam AI, Doctor Care Anywhere, Echo IQ. |
| What is the current market cap of Susmed? | Susmed's current market cap is $94.8M |
| What is the current revenue of Susmed? | Susmed's last 12 months revenue is $3.7M. |
| What is the current revenue growth of Susmed? | Susmed revenue growth (NTM/LTM) is 112%. |
| What is the current EV/Revenue multiple of Susmed? | Current revenue multiple of Susmed is 17.3x. |
| Is Susmed profitable? | Yes, Susmed is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
